ATE267838T1 - T-peptid und damit verwandte peptide in der behandlung von entzündungen einschlies slich der multiplen sklerose - Google Patents

T-peptid und damit verwandte peptide in der behandlung von entzündungen einschlies slich der multiplen sklerose

Info

Publication number
ATE267838T1
ATE267838T1 AT99101349T AT99101349T ATE267838T1 AT E267838 T1 ATE267838 T1 AT E267838T1 AT 99101349 T AT99101349 T AT 99101349T AT 99101349 T AT99101349 T AT 99101349T AT E267838 T1 ATE267838 T1 AT E267838T1
Authority
AT
Austria
Prior art keywords
absent
thr
ser
gly
treatment
Prior art date
Application number
AT99101349T
Other languages
English (en)
Inventor
Anders Jorgen Andersen
Roger Aston
Peter Louis Carlen
Penelope Reed Doob
David James Phipps
Douglas Kevin Macfadden
Deborah Rathjen
Fred Widmer
Original Assignee
Advanced Immuni T Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK92645A external-priority patent/DK64592D0/da
Application filed by Advanced Immuni T Inc filed Critical Advanced Immuni T Inc
Application granted granted Critical
Publication of ATE267838T1 publication Critical patent/ATE267838T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99101349T 1992-03-27 1993-03-29 T-peptid und damit verwandte peptide in der behandlung von entzündungen einschlies slich der multiplen sklerose ATE267838T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85883292A 1992-03-27 1992-03-27
DK92645A DK64592D0 (da) 1992-05-14 1992-05-14 Peptider til terapeutisk behandling
US91511892A 1992-07-17 1992-07-17
US98767492A 1992-12-09 1992-12-09

Publications (1)

Publication Number Publication Date
ATE267838T1 true ATE267838T1 (de) 2004-06-15

Family

ID=27439352

Family Applications (2)

Application Number Title Priority Date Filing Date
AT93907942T ATE194495T1 (de) 1992-03-27 1993-03-29 T-peptid und damit verwandte peptide in der behandlung von entzündungen einschliesslich der multiplen sklerose
AT99101349T ATE267838T1 (de) 1992-03-27 1993-03-29 T-peptid und damit verwandte peptide in der behandlung von entzündungen einschlies slich der multiplen sklerose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT93907942T ATE194495T1 (de) 1992-03-27 1993-03-29 T-peptid und damit verwandte peptide in der behandlung von entzündungen einschliesslich der multiplen sklerose

Country Status (12)

Country Link
EP (2) EP0635027B1 (de)
JP (1) JP3520084B2 (de)
KR (1) KR100312300B1 (de)
AT (2) ATE194495T1 (de)
AU (3) AU684713B2 (de)
CA (1) CA2132516A1 (de)
DE (2) DE69329023T2 (de)
DK (2) DK0635027T3 (de)
ES (2) ES2149203T3 (de)
PT (1) PT960886E (de)
UA (1) UA41881C2 (de)
WO (1) WO1993020102A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739109A (en) * 1988-12-16 1998-04-14 Advanced Immunit Inc. Method of treating neuroinflammatory degenerative diseases
DE69433817T2 (de) * 1993-09-24 2005-07-14 Advanced Immuni T, Inc. Lineare und cyklische peptide zur behandlung oder vorbeugung der crohn'schen krankheit und/oder der ulzerativen kolitis
US5798335A (en) * 1993-09-24 1998-08-25 Peptide Technology Limited Method for the treatment or prevention of eczema/dermatitis
CN1635913A (zh) * 1999-11-09 2005-07-06 先进伊姆尼特公司 通过施用t肽改变立即基因表达用于治疗病毒性疾病和其它失调的方法
JP4611233B2 (ja) * 2005-04-06 2011-01-12 ニッタ株式会社 歩行訓練支援装置
US20140322252A1 (en) * 2013-04-26 2014-10-30 Michael Ruff Peptides for Treating Alzheimers's Disease and Related Conditions
EP2832373B1 (de) * 2013-08-02 2017-04-12 Experimentelle Pharmakologie & Onkologie Berlin Buch Liposom zur Blockierung eines standortspezifischen chemokinassoziierten entzündlichen Prozesses bei Gefäßerkrankungen und Metastasen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7544987A (en) * 1986-06-03 1988-01-11 Pert, C.B. Small peptides which inhibit binding to t-4 receptors
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
WO1988009338A1 (en) * 1987-05-22 1988-12-01 Syntbiotech, Inc. Synthetic peptides and a method of treating aids
US5189022A (en) * 1988-05-27 1993-02-23 The United States Of America As Represented By The Secretary Of Health And Human Services Composition for the treatment of chronic fatigue syndrome
WO1989012067A1 (en) * 1988-05-27 1989-12-14 The United States Of America, As Represented By Th Compositions having use as treatment of psoriasis and neuropsychiatric deficits

Also Published As

Publication number Publication date
EP0635027B1 (de) 2000-07-12
DE69329023D1 (de) 2000-08-17
AU6354298A (en) 1998-06-18
UA41881C2 (uk) 2001-10-15
DE69333537T2 (de) 2005-06-16
AU684713B2 (en) 1998-01-08
DK0960886T3 (da) 2004-09-27
KR950700931A (ko) 1995-02-20
AU718442B2 (en) 2000-04-13
DE69333537D1 (de) 2004-07-01
DK0635027T3 (da) 2000-10-02
EP0635027A1 (de) 1995-01-25
DE69329023T2 (de) 2001-03-22
EP0960886B1 (de) 2004-05-26
CA2132516A1 (en) 1993-10-14
ATE194495T1 (de) 2000-07-15
KR100312300B1 (ko) 2002-03-20
JPH07507061A (ja) 1995-08-03
WO1993020102A1 (en) 1993-10-14
AU3895393A (en) 1993-11-08
PT960886E (pt) 2004-10-29
AU2254999A (en) 1999-05-20
ES2149203T3 (es) 2000-11-01
JP3520084B2 (ja) 2004-04-19
EP0960886A1 (de) 1999-12-01
AU725680B2 (en) 2000-10-19
ES2222625T3 (es) 2005-02-01

Similar Documents

Publication Publication Date Title
DE69627704T2 (de) Protegrine
ATE209215T1 (de) Protegrine
ATE108662T1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
SE9100799L (sv) Rekombinant derivat av human faktor viii
MD1443G2 (ro) Fracţie de copolimer-1, procedeu de obţinere a ei şi compoziţii pe baza acesteia pentru tratamentul sclerozei diseminate
DE59007517D1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
ATE171712T1 (de) Neuartiger menschlicher proteaseinhibitor vom kunitz-typ und entsprechende varianten
DK0573538T3 (da) Peptider til behandling
ATE267838T1 (de) T-peptid und damit verwandte peptide in der behandlung von entzündungen einschlies slich der multiplen sklerose
RU94027578A (ru) Фармацевтическая композиция и способ лечения рассеянного склероза
EP0621285A4 (de) Neuer megakaryocyten-verstärker.
ATE3773T1 (de) An peptide polymerisationsprodukte gebundene muramyl-peptide und sie enthaltende pharmazeutische zusammensetzungen.
CA2102606A1 (en) Compositions for the treatment of chronic fatigue syndrome
ATE308617T1 (de) Rantes mutanten und deren therapeutischen anwendungen
Carrell et al. Structural mobility of antithrombin and its modulation by heparin
ATE120758T1 (de) Peptide, deren verwendung als hemmer gegen entwicklung von t-lymphocyten und wirksamkeit von makrophagen und verfahren zu deren herstellung.
RU94046096A (ru) Линейные или циклические пептиды, их применение, способы лечения и конъюгаты пептидов
DE3751398D1 (de) Substrat-Peptide.
DE68905097D1 (de) Peptid-molekuele, wirksam gegen gram-positive keime.
RU94036002A (ru) Ингибитор протеазы, днк, вектор, клетка, способ получения ингибитора, фармацевтическая композиция

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0960886

Country of ref document: EP

REN Ceased due to non-payment of the annual fee